Bird & Bird advises Exciva on EUR 9 million Series A funding round

Bird & Bird has advised Heidelberg-based Exciva GmbH, a clinical biotech company which is developing a novel therapy for the treatment of agitation and aggression in Alzheimer's disease, in its Series A financing led by Andera Partners amounting to EUR 9 million. LBBW Venture Capital and Cure8 also participated in the financing round.

The initial funding will be used by Exciva to develop its lead product to Phase I completion. The compound is a combination of two clinically approved products that have a proven efficacy in treating the central nervous system.

Exciva GmbH was advised by the following Bird & Bird lawyers: Associate Marcel Nurk, partner Stefan Münch and counsel Michael Gaßner, all corporate law/M&A, Munich.


News & Deals

More News & Deals

News

Bird & Bird continues sponsoring Slush Investor Day, reinforcing commitment to Nordic tech investment

Sep 13 2024

Read More

News

Bird & Bird’s Aviation team in Asia-Pacific ranks 2nd in AFG Legal Survey

Sep 12 2024

Read More

Deal

Bird & Bird has advised East Japan Railway Company in the sale of Decorum Vending Limited

Sep 11 2024

Read More

Deal

Bird & Bird advised Capital Croissance on its investment in Aether FS

Sep 09 2024

Read More

Deal

Bird & Bird acts as sell-side legal advisor to Vitruvian Partners on its sale of Benify

Sep 06 2024

Read More

Deal

Bird & Bird advise Leo Capital on launching their first Nordic Fund

Sep 05 2024

Read More